Literature DB >> 16917737

Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma.

Masayoshi Nagamine1, Miki Takahara, Kan Kishibe, Toshihiro Nagato, Hideyuki Ishii, Nobuyuki Bandoh, Takeshi Ogino, Yasuaki Harabuchi.   

Abstract

Nasal natural killer (NK)/T-cell lymphoma is a peculiar lymphoma with an unique immunophenotype. Etiologically, the authors previously first demonstrated the presence of Epstein-Barr virus (EBV) genomes and their products in this lymphoma (Lancet 1990; 335). It is suggested that some of sequence variations such as a 30-bp deletion and multiple base substitutions and as amino acid changes at HLA-A2 restricted CTL epitopes were associated with an increase in tumorigenicity and with a decrease in immune recognition. In this study, we determined full-length of LMP1 sequence isolated from 7 patients with nasal NK/T-cell lymphoma using polymerase chain reaction (PCR) method and compared the sequences with those referred to previous reports. In the carboxyl-terminal site, all 7 patients showed 4 copies of the 11 amino acids repeat (codon 254-302) and 30-bp deletion corresponding to codon 343-352 of the B95-8 strain. Within the NF-kB-activating domains, all 7 patients showed amino acid changes at codon 189 (Gln to Pro), 192 (Ser to Thr) and 212 (Gly to Ser) on either site of the PXQXT (codon 204-208) motif. In the major HLA-A2 restricted T-cell epitope sequence YLLEMLWRL (codon 125-133), all 7 patients showed amino acid changes at codon 126 (Leu to Phe) and 129 (Met to Ile). In the epitopes ALLVLYSFA (codon 51-59), VLFIFGCLL (codon 110-118) and WLLLFLAIL (codon 173-181), several patients showed novel amino acid changes at codon 59 (Ala to Gly), 110 (Val to Leu) and 174 (Leu to Ile), respectively. Although it is still not clear what the most specific and biologic variation of LMP1 gene in nasal NK/T-cell lymphoma is, the sequence data may be valuable on the study for pathogenesis of nasal NK/T-cell lymphoma and EBV molecular epidemiology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917737     DOI: 10.1007/s11262-006-0008-5

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  47 in total

1.  Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus.

Authors:  H Nagata; A Konno; N Kimura; Y Zhang; M Kimura; A Demachi; T Sekine; K Yamamoto; N Shimizu
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

2.  Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.

Authors:  A K Chiang; Q Tao; G Srivastava; F C Ho
Journal:  Int J Cancer       Date:  1996-11-04       Impact factor: 7.396

3.  In nasopharyngeal carcinoma-bearing patients, tumors and lymphocytes are infected by different Epstein-Barr virus strains.

Authors:  S Henry; C Sacaze; L Berrajah; H Karray; M Drira; A Hammami; J Icart; B Mariame
Journal:  Int J Cancer       Date:  2001-03-01       Impact factor: 7.396

4.  Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage.

Authors:  A K Chiang; A C Chan; G Srivastava; F C Ho
Journal:  Int J Cancer       Date:  1997-11-04       Impact factor: 7.396

5.  Nasal lymphomas in Japan: a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene.

Authors:  J Suzumiya; K Ohshima; M Takeshita; M Kanda; C Kawasaki; N Kimura; K Tamura; M Kikuchi
Journal:  Leuk Lymphoma       Date:  1999-11

6.  Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation.

Authors:  O Devergne; E Hatzivassiliou; K M Izumi; K M Kaye; M F Kleijnen; E Kieff; G Mosialos
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

7.  Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies.

Authors:  Y Harabuchi; S Imai; J Wakashima; M Hirao; A Kataura; T Osato; S Kon
Journal:  Cancer       Date:  1996-05-15       Impact factor: 6.860

8.  Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population.

Authors:  M L Chen; C N Tsai; C L Liang; C H Shu; C R Huang; D Sulitzeanu; S T Liu; Y S Chang
Journal:  Oncogene       Date:  1992-11       Impact factor: 9.867

9.  Midfacial T cell lymphoma: characterization by monoclonal antibodies.

Authors:  N Yamanaka; A Kataura; S Sambe; T Minase; Y Ishii
Journal:  Ann Otol Rhinol Laryngol       Date:  1985 Mar-Apr       Impact factor: 1.547

10.  Lethal midline granuloma (granuloma gangraenescens) at autopsy; report of a case and review of literature.

Authors:  G S SPEAR; W G WALKER
Journal:  Bull Johns Hopkins Hosp       Date:  1956-12
View more
  18 in total

1.  Comparative analysis of oncogenic properties and nuclear factor-kappaB activity of latent membrane protein 1 natural variants from Hodgkin's lymphoma's Reed-Sternberg cells and normal B-lymphocytes.

Authors:  Nathalie Faumont; Aurélie Chanut; Alan Benard; Nadine Cogne; Georges Delsol; Jean Feuillard; Fabienne Meggetto
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

Review 2.  Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Authors:  Bradley M Haverkos; Carrie Coleman; Alejandro A Gru; Zenggang Pan; Jonathan Brammer; Rosemary Rochford; Anjali Mishra; Christopher C Oakes; Robert A Baiocchi; Aharon G Freud; Pierluigi Porcu
Journal:  Discov Med       Date:  2017-03       Impact factor: 2.970

3.  Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.

Authors:  Ningjing Lin; Wenjing Ku; Yuqin Song; Jun Zhu; Zheming Lu
Journal:  Oncologist       Date:  2019-04-02

Review 4.  Natural killer cell neoplasm: biology and pathology.

Authors:  Maria Francisca Ham; Young-Hyeh Ko
Journal:  Int J Hematol       Date:  2010-12-07       Impact factor: 2.490

5.  Analysis of EBNA-1 and LMP-1 variants in diseases associated with EBV infection in Chinese children.

Authors:  Junhong Ai; Zhengde Xie; Chunyan Liu; Zhizuo Huang; Junmei Xu
Journal:  Virol J       Date:  2012-01-11       Impact factor: 4.099

Review 6.  The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal.

Authors:  Cindy M Chang; Kelly J Yu; Sam M Mbulaiteye; Allan Hildesheim; Kishor Bhatia
Journal:  Virus Res       Date:  2009-07-23       Impact factor: 3.303

7.  Epstein-Barr virus genetic variation in Vietnamese patients with nasopharyngeal carcinoma: full-length analysis of LMP1.

Authors:  Do Nguyen-Van; Ingemar Ernberg; Ingemar Enrberg; Phi Phan-Thi Phi; Chinh Tran-Thi; LiFu Hu
Journal:  Virus Genes       Date:  2008-07-29       Impact factor: 2.332

8.  Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma.

Authors:  Susanna H Hutajulu; Eveline K Hoebe; Sandra Awm Verkuijlen; Jajah Fachiroh; Bambang Hariwijanto; Sofia M Haryana; Servi Jc Stevens; Astrid E Greijer; Jaap M Middeldorp
Journal:  Infect Agent Cancer       Date:  2010-09-19       Impact factor: 2.965

Review 9.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

10.  Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.

Authors:  Ivonne A Montes-Mojarro; Bo-Jung Chen; Ana F Ramirez-Ibarguen; Carmen M Quezada-Fiallos; Wendy B Pérez-Báez; Daniela Dueñas; Sandro Casavilca-Zambrano; Marcela Ortiz-Mayor; Erica Rojas-Bilbao; Hernan García-Rivello; Maria F Metrebian; Marina Narbaitz; Carlos Barrionuevo; Carmen Lome-Maldonado; Irina Bonzheim; Falko Fend; Julia Steinhilber; Leticia Quintanilla-Martinez
Journal:  Mod Pathol       Date:  2019-12-10       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.